<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Digitalization</title>
	<atom:link href="http://www.tapanray.in/tag/digitalization/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Using Selling Simulator For New Drug Launch In The New Normal</title>
		<link>http://www.tapanray.in/using-selling-simulator-for-new-drug-launch-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=using-selling-simulator-for-new-drug-launch-in-the-new-normal</link>
		<comments>http://www.tapanray.in/using-selling-simulator-for-new-drug-launch-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 23 Aug 2021 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[doctos]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[marketer]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[online]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remote]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[simulation]]></category>
		<category><![CDATA[simulator]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[training]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[unprecedented]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10574</guid>
		<description><![CDATA[The reverberation of unparalleled business disruptions in healthcare caused by Covid pandemic, extends across its value chain &#8211; from patients and families to clinicians and pharmaceutical companies. Consequently, even many diehards or staunchly tradition-bound pharma marketers were being prompted to reimagine their &#8230; <a href="http://www.tapanray.in/using-selling-simulator-for-new-drug-launch-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/using-selling-simulator-for-new-drug-launch-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Still Evolving: Pharma’s New Pathway For Digital And F2F Customer Engagement</title>
		<link>http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement</link>
		<comments>http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/#comments</comments>
		<pubDate>Mon, 15 Feb 2021 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[areas]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Customer-Engagement]]></category>
		<category><![CDATA[Digital F2F]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[e-marketing]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[Evolving. Pharma]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[inbound]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interactions]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[outbound]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[preference]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[times]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[uncertain]]></category>
		<category><![CDATA[visits]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10415</guid>
		<description><![CDATA[Last year &#8211; probably left with no better choice &#8211; the pharma industry, in general, had to take an unprecedented interest in digitalization of business processes. It happened faster than ever, especially in the marketing domain, along with a few &#8230; <a href="http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/still-evolving-pharmas-new-pathway-for-digital-and-f2f-customer-engagement/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>2020: Learnings From A Yearlong Catastrophic Disruption And Crystal-Gazing 2021</title>
		<link>http://www.tapanray.in/2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021</link>
		<comments>http://www.tapanray.in/2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021/#comments</comments>
		<pubDate>Mon, 28 Dec 2020 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2020]]></category>
		<category><![CDATA[2021]]></category>
		<category><![CDATA[anti-infective]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[crystal-gazing]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[hubris]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[inorganic]]></category>
		<category><![CDATA[learning]]></category>
		<category><![CDATA[Meeting]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[new drugs]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[rollout]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10383</guid>
		<description><![CDATA[ Wishing All My Readers A Very Happy, Healthy, Peaceful and Prosperous 2021 Just a few days left for the year 2020 to merge with history. It will be remembered by all &#8211; as a year of all-round catastrophic global disruption. &#8230; <a href="http://www.tapanray.in/2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/2020-learnings-from-a-yearlong-catastrophic-disruption-and-crystal-gazing-2021/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Time For Pharma To Leverage ‘The Break In The Clouds’</title>
		<link>http://www.tapanray.in/time-for-pharma-to-leverage-the-break-in-the-clouds/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=time-for-pharma-to-leverage-the-break-in-the-clouds</link>
		<comments>http://www.tapanray.in/time-for-pharma-to-leverage-the-break-in-the-clouds/#comments</comments>
		<pubDate>Mon, 06 Jul 2020 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Alternative]]></category>
		<category><![CDATA[break in the clouds]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[groundswell]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leverage]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[prerequisites]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reimagine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10157</guid>
		<description><![CDATA[A ‘break in the clouds’ is now clearly visible in the dark and overcast sky &#8211; witnessing a global havoc caused by the Coronavirus pandemic in the healthcare space &#8211; with its severe socioeconomic consequences. The name of the game &#8230; <a href="http://www.tapanray.in/time-for-pharma-to-leverage-the-break-in-the-clouds/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/time-for-pharma-to-leverage-the-break-in-the-clouds/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Time For Predictive Rather Than Reactive Pharma Strategy</title>
		<link>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=time-for-predictive-rather-than-reactive-pharma-strategy</link>
		<comments>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/#comments</comments>
		<pubDate>Mon, 15 Jun 2020 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[first in class]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[me-too]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[predictive]]></category>
		<category><![CDATA[proactive]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reactive]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[sailing]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[value-based]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10126</guid>
		<description><![CDATA[Traditionally, pharmaceutical industry, across the world, is mostly reactive &#8211; rather than proactive or predictive in its strategic approach &#8211; spanning across all its business domains. A large number of pharma players &#8211; both innovators and generic drug makers, formulate &#8230; <a href="http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Post Covid-19 Lockdown: Is Pharma Industry Ready?</title>
		<link>http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=post-covid-19-lockdown-is-pharma-industry-ready</link>
		<comments>http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/#comments</comments>
		<pubDate>Mon, 27 Apr 2020 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[customer-centric]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[distancing]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[herd-immunity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[Oxford]]></category>
		<category><![CDATA[physical]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ready]]></category>
		<category><![CDATA[remdesivir]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Social-distancing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10033</guid>
		<description><![CDATA[It’s over a month now since national lockdown in India came into force to win the war against Covid-19. Many promises and apprehensions about whether or not Covid-19 will keep ravaging human life, continue surfacing. As it appears today, whatever &#8230; <a href="http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Pharma Industry A Late Learner, Always?</title>
		<link>http://www.tapanray.in/is-pharma-industry-a-late-learner-always/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-pharma-industry-a-late-learner-always</link>
		<comments>http://www.tapanray.in/is-pharma-industry-a-late-learner-always/#comments</comments>
		<pubDate>Mon, 23 Dec 2019 00:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Consumerism]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[diagnosis]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[E-Patients]]></category>
		<category><![CDATA[empowerment]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[episodes]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[fast]]></category>
		<category><![CDATA[Ferguson]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[late]]></category>
		<category><![CDATA[learner]]></category>
		<category><![CDATA[learning]]></category>
		<category><![CDATA[legacy]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reinvent the wheel]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thomas]]></category>
		<category><![CDATA[touchpoints]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9826</guid>
		<description><![CDATA[Several upcoming concepts in the pharmaceutical industry are becoming buzzwords today. But, most of these were recommended by stalwarts several decades ago. Interestingly, the prevailing scenario is no different, even related to wide-scale adoption of a number of cutting-edge technologies, &#8230; <a href="http://www.tapanray.in/is-pharma-industry-a-late-learner-always/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-pharma-industry-a-late-learner-always/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Link To Ponder: Pharma Digitalization – Cyber Threats &#8211; Cyber Immunity</title>
		<link>http://www.tapanray.in/a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity</link>
		<comments>http://www.tapanray.in/a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity/#comments</comments>
		<pubDate>Mon, 04 Nov 2019 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[attacks]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[criminals]]></category>
		<category><![CDATA[cyber]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[immunity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[ponder]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9776</guid>
		<description><![CDATA[Digitalization in the pharmaceutical industry – slowly but steadily, across its various domains, from drug discovery, clinical development, supply chain, sales and marketing to engage with various stakeholders, is a reality today. Consequently, the concept of data as a business &#8230; <a href="http://www.tapanray.in/a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-link-to-ponder-pharma-digitalization-cyber-threats-cyber-immunity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma: ‘Digitalization’ Not A Panacea – A Basic Step For Giant Leaps</title>
		<link>http://www.tapanray.in/pharma-digitalization-not-a-panacea-a-basic-step-for-giant-leaps/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-digitalization-not-a-panacea-a-basic-step-for-giant-leaps</link>
		<comments>http://www.tapanray.in/pharma-digitalization-not-a-panacea-a-basic-step-for-giant-leaps/#comments</comments>
		<pubDate>Mon, 07 Oct 2019 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[backbone]]></category>
		<category><![CDATA[basic]]></category>
		<category><![CDATA[bedrock]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[digitization]]></category>
		<category><![CDATA[dilemma]]></category>
		<category><![CDATA[domains]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[Leap]]></category>
		<category><![CDATA[panacea]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transformation]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9736</guid>
		<description><![CDATA[The hype of ‘Digitalization’ in the pharma industry, virtually as a panacea, is palpable all around. It gives many a feel, directly or indirectly, that this one-time, resource-intensive, disruptive transformation would reap a rich harvest for a long time. In &#8230; <a href="http://www.tapanray.in/pharma-digitalization-not-a-panacea-a-basic-step-for-giant-leaps/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-digitalization-not-a-panacea-a-basic-step-for-giant-leaps/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Data: The New ‘Magic Wand’ For Pharma Business Excellence?</title>
		<link>http://www.tapanray.in/data-the-new-magic-wand-for-pharma-business-excellence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-the-new-magic-wand-for-pharma-business-excellence</link>
		<comments>http://www.tapanray.in/data-the-new-magic-wand-for-pharma-business-excellence/#comments</comments>
		<pubDate>Mon, 01 Oct 2018 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[analytics]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[Corruption]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[Generation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[magic]]></category>
		<category><![CDATA[Notes]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Playbook]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rewriting]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[wand]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9166</guid>
		<description><![CDATA[Pharma companies focus more on defending their current practices, rather than doing things differently. A September 24, 2014 article by Bain &#38; Company, titled ‘New Paths to Value Creation in Pharma’, made this observation. This happens regardless of the credence that &#8230; <a href="http://www.tapanray.in/data-the-new-magic-wand-for-pharma-business-excellence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-the-new-magic-wand-for-pharma-business-excellence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
